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OBJECTIVES We examined whether a relationship exists between the vasoconstrictive response to
endogenous nitric oxide (NO) synthesis inhibition and the severity of heart failure in patients
with congestive heart failure (CHF).
BACKGROUND Controversy exists as to whether the vasoconstrictive response to NO synthesis inhibition in
patients with CHF is comparable to that in normal subjects or is enhanced.
METHODS Forearm blood flow (FBF) and calculated forearm vascular conductance (FVC) were obtained
using plethysmography before and after administration of the NO synthesis inhibitor
L-NMMA (NG-monomethyl-L-arginine) in 40 patients with CHF due to dilated cardio-
myopathy and in 16 normal control subjects. Basal plasma B-type natriuretic peptide (BNP)
and nitric oxide concentrations were measured in all subjects.
RESULTS Plasma BNP and nitrite/nitrate (NOx) levels in the patients group were significantly greater
and baseline FBF was significantly less. Administration of L-NMMA significantly decreased
FBF and FVC in both groups. The percent changes in FBF (%FBF) and FVC (%FVC) from
the baseline after L-NMMA correlated significantly with plasma BNP level (%FBF: r 5 0.72;
%FVC: r 5 0.76; both p , 0.001). Percent changes in both FBF and FVC were greater in
patients with BNP $ 100 pg/ml than in normal subjects; however, in patients with BNP ,
100 pg/ml they were comparable to those in normal subjects.
CONCLUSIONS Vasoconstrictive response to L-NMMA in patients with CHF was preserved or enhanced in
proportion to the basal plasma BNP level, indicating a close relationship between the
contribution of endogenous NO to basal vasomotor tone and the severity of heart failure.
(J Am Coll Cardiol 2000;36:1605–11) © 2000 by the American College of Cardiology
Endothelium-derived nitric oxide (NO) plays a pivotal
role in the regulation of the vasomotor tone of peripheral
vessels. Vallance et al. (1) first showed that basal release
of NO, which accounts for the biological activity of
endothelium-derived relaxing factor, contributes to the
control of regional blood flow in humans, using NG-
monomethyl-L-arginine (L-NMMA), a selective inhibi-
tor of NO synthesis from L-arginine (2). In patients with
congestive heart failure (CHF), agonist-induced NO-
mediated vasodilatation in response to muscarinic stim-
ulation is impaired in the peripheral circulation (3–5). By
contrast, there are conflicting results showing that vaso-
constrictive response to the administration of L-NMMA,
indicating the basal production and release of NO,
decreases (6), remains normal (7), or increases (8 –10) in
patients with CHF compared with that of normal sub-
jects. Differences in the results of these previous studies
may be related to differences in the severity or the
etiology of heart failure in the study populations. A
recent study demonstrated that there was no difference in
vasoconstrictive response to L-NMMA in patients with
moderate heart failure in New York Heart Association
(NYHA) functional class I and class II and normal
subjects but that the vasoconstrictive response in patients
with severe heart failure in NYHA functional class III
and class IV was significantly less than that in normal
subjects (11).
In the present study, to examine whether the basal
production of NO in patients with CHF might be related
to the severity of heart failure, we used the basal plasma
level of B-type natriuretic peptide (BNP) for classifying
the degree of heart failure instead of using NYHA
classification, because the plasma BNP level is more
objective than NYHA classification. Although both atrial
natriuretic peptide (ANP) and BNP levels increase in
patients with CHF, the circulating level of BNP has been
reported to increase in proportion to the functional
severity of heart failure to a greater extent than that of
ANP (12,13). We therefore designed this study to
determine whether the degree to which L-NMMA affects
peripheral vasomotor tone is related to the plasma BNP
level of patients with CHF.
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METHODS
Subjects. Forty-six patients with CHF due to idiopathic
dilated cardiomyopathy who had been admitted to our
hospital and 16 age- and gender-matched healthy control
volunteers were enrolled in this study. The patient group
included 28 men and 18 women with a mean age of 60 years
(range 44 to 76 years). The control group consisted of 10
men and 6 women with a mean age of 58 years (range 36 to
78 years) who showed no abnormalities upon physical
examination, electrocardiography, chest radiography, and
routine blood tests including fasting blood sugar and serum
cholesterol. Current smokers and subjects who had smoked
within two years were excluded from this study.
Patients with renal dysfunction (serum creatinine
$1.2 mg/dl) were not enrolled in the study, because the
plasma level of BNP is affected by renal function (14). All
patients underwent cardiac catheterization to measure car-
diac hemodynamics and to perform left ventriculography
and coronary angiography. Two patients with organic cor-
onary stenotic lesions .75% were excluded from the study.
Four patients with transient atrial fibrillation detected
within seven days before the study were also excluded
because it has been proposed that atrial fibrillation decreases
endothelium-dependent vasodilatation and NO production
(15). Mean left ventricular ejection fraction obtained by
catheterization in the remaining 40 patients with CHF was
26 6 8%. Cardiac index was 2.16 6 0.71 liter/min/m2, and
mean pulmonary capillary wedge pressure was 19 6
8 mm Hg. In terms of the clinical severity of heart failure,
the patients were in NYHA functional classes I to III. All
patients had been clinically stable for at least two weeks
before the study, with no signs of pulmonary congestion or
peripheral edema. Background therapies were digoxin (n 5
29), diuretics (n 5 30), angiotensin-converting enzyme
(ACE) inhibitors (n 5 20), nitrates (n 5 12), calcium
antagonists (n 5 5) and anticoagulants (n 5 13). All
vasodilating medications and anticoagulants were discontin-
ued two or three days before the day of the study, and
digitalis and diuretics were stopped on the day of the study.
During this period, the patients were closely monitored for
any sign of aggravation of heart failure. All patients and
control subjects gave their written, informed consent to
participation in the study, which had been approved by the
Human Subjects Research Committee of Shimane Medical
University Hospital.
Procedures and protocols. All participants were instructed
to abstain from eating food and drinking caffeinated bever-
ages for at least 12 h before the study, which was performed
in the supine position in an air-conditioned room at a
temperature of 25–26°C. Forearm blood flow (FBF) was
determined by venous occlusion plethysmography as de-
scribed elsewhere (16). Briefly, under local anesthesia with
1% lidocaine, the brachial artery of the nondominant arm
(the left arm) was cannulated with a 22-gauge polyethylene
catheter (RA-4122, Arrow, Reading, Pennsylvania) for
pressure monitoring and drug infusion. A 24-gauge poly-
ethylene catheter was placed in the basilica vein for venous
blood sampling. This arm was slightly elevated above the
level of the right atrium, and a mercury-filled silicone
strain-gauge was placed in the widest part of the forearm.
The strain-gauge was connected to a Hokanson EC-5R
Plethysmograph (Hokanson, Bellevue, Washington) that
was calibrated to measure the percent change in volume and
connected in turn to a chart recorder to record the flow
measurements. For each measurement, a cuff placed around
the upper arm was inflated to 40 mm Hg with a rapid cuff
inflator (E-10, Hokanson) to occlude venous outflow from
the extremity. A wrist cuff was inflated to suprasystolic
pressure 1 min before each measurement to exclude the
hand circulation. Flow measurements were recorded for 5 s
every 15 s, and four readings were obtained for each mean
value. Systemic blood pressure was measured with a cuff
sphygmomanometer placed on the contralateral arm, and
arterial pressure on the side of FBF measurements was
continuously monitored with a Life Scope 12 polygraph
(Nihonkoden, Tokyo, Japan). Forearm vascular conduc-
tance (FVC) was calculated by dividing FBF by the mean
arterial pressure.
After a 20-min rest period, blood samples were obtained
for measurements of baseline ANP, BNP and nitric oxide
(NOx: nitrite/nitrate) levels. After baseline FBF was mea-
sured, L-NMMA (100 mmol, Clinalfa, La¨ufelfingen, Swit-
zerland) was infused over 5 min. Five minutes after com-
pletion of the infusion, FBF was measured again.
Measurement of plasma ANP, BNP, and NOx concen-
trations. Venous plasma ANP and BNP levels were deter-
mined using commercially available radioimmunoassay kits
(Shionoria, Shionogi, Osaka, Japan). In this assay, the
minimal detectable quantities of ANP and BNP are 5 pg/ml
and 2 pg/ml, respectively, and cross-reactivities with other
natriuretic peptides are ,0.001% on a molar basis. Venous
nitrite/nitrate (NOx) levels were measured using the fluoro-
metric method reported previously (17,18). Briefly, plasma
was incubated with NADPH and Aspergillus niger nitrate
reductase (Sigma Chemical, St. Louis, Missouri) and sub-
sequently with 2,3-diaminonaphthalene (Dojindo Labs,
Kumamoto, Japan). Fluorescence intensity was measured
with a Hitachi 850 fluorescence spectrophotometer (Hitachi
Co., Tokyo, Japan). Nitrite standards (.98% pure, Sigma
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
ANOVA 5 analysis of variance
BNP 5 B-type natriuretic peptide
CHF 5 congestive heart failure
FBF 5 forearm blood flow
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L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NOx 5 nitrite/nitrate
NYHA 5 New York Heart Association
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Chemical) were freshly prepared. Nitrite was detectable at a
concentration of 10 pmol/ml.
Statistical analysis. Data are expressed as mean 6 SD
unless otherwise indicated. Intergroup differences were an-
alyzed with the chi-square test or unpaired t tests for
baseline characteristics, except for ANP, BNP and NOx
levels. Either the Mann-Whitney U test or Kruskall-Wallis
analysis of variance (ANOVA) followed by Scheffe’s post
hoc test was used to compare the nonparametric variables
ANP, BNP and NOx. Responses to L-NMMA were com-
pared with two-way (group and drug treatment) ANOVA
for repeated measures. When significant differences were
observed, comparison within groups or drug treatments was
performed with one-way ANOVA followed by the Scheffe
test. Correlations between measured variables of interest
were determined by simple linear regression analysis, and
differences in changes in FBF and FVC after administration
of L-NMMA were compared using analysis of covariance
with baseline FBF or FVC as a covariate to adjust for
differences in basal FBF and FVC. A value of p , 0.05 was
considered statistically significant.
RESULTS
Clinical characteristics of the study population. Baseline
clinical characteristics of the study participants are shown in
Table 1. Blood pressure and heart rate tended to be higher
in the CHF patients than in the control subjects, but the
differences were not significant. The CHF patients showed
evidence of hormonal activation, in the form of distinctly
higher plasma ANP and BNP levels, than did control
subjects (p , 0.001). Plasma NOx levels were also signifi-
cantly higher in the CHF patients than in controls (p ,
0.001).
Effects of L-NMMA on baseline FBF and FVC. Individ-
ual L-NMMA–induced changes in FBF are shown in
Figure 1, and mean values by BNP level are listed in Table
2. Baseline values for FBF and FVC were 3.66 6
0.72 ml/min/dl and 4.1 6 0.8 3 1022 ml/min/dl/mm Hg in
the control group and 2.74 6 0.76 ml/min/dl and 3.1 6
1.3 3 1022 ml/min/dl/mm Hg in the CHF patient group
(all patients). Differences between the two groups were
significant (FBF: p 5 0.002; FVC: p , 0.001). Adminis-
tration of L-NMMA did not alter the heart rate or the blood
pressure in either group, but it significantly lowered baseline
FBF to 2.54 6 0.55 ml/min/dl (p , 0.001) in the control
group and to 1.89 6 0.63 ml/min/dl (p , 0.001) in the
CHF group. Also, FVC significantly decreased after
L-NMMA in both groups (p , 0.001). Average decrease in
both FBF and FVC did not differ between the control and
patient groups (absolute change in FBF: 21.12 6 0.28 vs.
20.87 6 0.39 ml/min/dl, p 5 0.08; percent change in FBF:
231 6 5 vs. 232 6 11%, p 5 0.38; percent change in
FVC: 234 6 5 vs. 238 6 13%, p 5 0.33).
We then compared five patient groups, based on their
plasma BNP levels: BNP ,50 pg/ml; 50 #BNP
,100 pg/ml; 100 #BNP ,200 pg/ml; 200 #BNP
,300 pg/ml; and BNP $300 pg/ml. The L-NMMA
significantly lowered the FBF and FVC in patients in the
BNP $100 pg/ml range. By contrast, in patients with BNP
,100 pg/ml, FBF and FVC tended to decrease after
administration of L-NMMA, but the differences were not
significant. Percent changes in FBF and FVC in patients
with BNP ,100 pg/ml were comparable to those in the
control group, whereas they were significantly greater in
patients with BNP $100 pg/ml.
In both groups, FBF measured on the contralateral
forearm did not change significantly after administration of
L-NMMA.
Relationship between percent changes in FBF and FVC
after L-NMMA and plasma BNP levels. The percent
changes in FBF after L-NMMA closely correlated with the
plasma BNP levels (n 5 56; r 5 0.72; p , 0.001), and the
percent changes in FVC also correlated significantly with
Figure 1. Forearm blood flow before and after administration of
L-NMMA in control subjects (left panel) and in patients with congestive
heart failure (CHF) (right panel).
Table 1. Clinical Characteristics of Study Population
Control CHF
Number (n) 16 40
Gender (M/F) 10/6 23/7
Age (yrs) 58 6 11 59 6 10
NYHA functional class I (n) (12)
NYHA functional class II (n) (14)
NYHA functional class III (n) (14)
Total cholesterol (mg/dl) 177 6 25 180 6 29
Triglyceride (mg/dl) 78 6 34 90 6 32
HDL cholesterol (mg/dl) 53 6 8 56 6 7
LDL cholesterol (mg/dl) 109 6 24 110 6 27
Fasting blood sugar (mg/dl) 91 6 7 96 6 10
Atrial natriuretic peptide (pg/ml) 7 6 3 74 6 81*
Brain natriuretic peptide (pg/ml) 4 6 2 244 6 187*
Nitrite and nitrate (mmol/liter) 4 6 3 17 6 15*
Heart rate (beats/min) 57 6 7 64 6 11
Systolic blood pressure (mm Hg) 115 6 9 118 6 10
Diastolic blood pressure (mm Hg) 67 6 7 69 6 14
Values are mean 6 SD. CHF 5 congestive heart failure.
*p , 0.001 vs. corresponding value in control.
1607JACC Vol. 36, No. 5, 2000 Ishibashi et al.
November 1, 2000:1605–11 Increased NO Production in Patients With Severe Heart Failure
the plasma BNP levels (n 5 56; r 5 0.76; p , 0.001) (Fig.
2).
Relationship between percent changes in FBF and FVC
after L-NMMA and plasma NOx levels. The percent
changes in FBF and FVC after L-NMMA infusion corre-
lated weakly but significantly with the levels of plasma NOx
levels (n 5 56; r 5 0.60, p 5 0.003 and r 5 0.66, p , 0.001,
respectively; both p , 0.001) (Fig. 3). By contrast, the
absolute changes in FBF after L-NMMA infusion did not
correlate with either NOx or BNP levels (n 5 56; r 5 0.08,
p 5 0.96; and r 5 0.01, p 5 0.93, respectively), whereas it
did correlate significantly with baseline FBF (n 5 56; r 5
0.65; p , 0.001) (not shown).
DISCUSSION
The present data demonstrate that the contribution of
endogenous NO to the basal vasomotor tone of the periph-
eral vessels in the CHF patients varied according to the
plasma BNP level. Thus, the percent changes in FBF and
FVC after L-NMMA infusion in patients with CHF with
BNP ,100 pg/ml were comparable to those in control
subjects, and in patients with BNP $100, they were
significantly greater. These findings suggest that the basal
production and release of NO in patients with CHF may
vary according to the severity of heart failure. Our results
may help to resolve certain issues in previous studies that
investigated different patient populations.
Previous studies in humans. Drexler et al. (8) reported
that an L-NMMA–induced decrease in FBF calculated
from vessel diameter and blood flow velocity using echocar-
diography was greater in patients with CHF (46%) than in
normal control subjects (38%), and they emphasized that
blocking of basal NO release caused an exaggerated vaso-
constrictive response in patients with CHF. Similarly,
following systemic administration of L-NMMA, Habib et
al. (9) found the highest increase in systemic vascular
resistance after L-NMMA administration in those CHF
patients with the highest basal systemic vascular resistance.
In addition, Winlaw et al. (10) reported measurements of
increased plasma nitrate levels in patients with CHF. These
previous observations suggest that the production and re-
lease of NO in the basal state is enhanced in patients with
CHF.
By contrast, Kubo et al. (7) reported no significant
differences between normal subjects and patients with CHF
in either absolute or percent change in FBF during infusion
of graded doses of L-NMMA. In that study, the mean
Table 2. Effects of L-NMMA on FBF and FVC in Range of Plasma BNP Level
n
BNP
(pg/ml)
NOx
(mmol/liter)
FBF
(ml/min/dl)
% Change
FVC
(31022 ml/min/dl/mm Hg)
% ChangeBaseline L-NMMA Baseline L-NMMA
Control 16 4 6 2 4 6 3 3.66 6 0.72 2.54 6 0.55‡ 231 6 5 4.1 6 0.8 2.7 6 0.6‡ 234 6 5
CHF all patients 40 244 6 187** 17 6 15* 2.74 6 0.76* 1.89 6 0.63*‡ 232 6 11 3.1 6 1.3* 1.9 6 0.6*‡ 238 6 13
BNP , 50 7 31 6 13 5 6 4 2.96 6 0.87 2.31 6 0.66 222 6 12 3.2 6 0.9 2.3 6 0.9 229 6 13
50 # BNP ,100 7 77 6 20* 14 6 15 2.95 6 0.54 2.37 6 0.33 221 6 14 3.1 6 0.8 2.4 6 0.5 228 6 15
100 # BNP ,200 10 157 6 30* 18 6 11* 2.88 6 0.66 1.87 6 0.50† 237 6 7 3.1 6 0.6 1.8 6 0.4*‡ 241 6 7*
200 # BNP ,300 7 248 6 19** 19 6 10* 2.85 6 0.78 1.78 6 0.46*† 243 6 8* 3.2 6 0.6 1.7 6 0.3*† 246 6 9*
300 # BNP 9 462 6 189** 30 6 20* 2.13 6 0.82** 1.18 6 0.46**† 247 6 9** 2.7 6 0.8** 1.4 6 0.5**‡ 251 6 9**
Values are mean 6 SD. CHF 5 congestive heart failure; FBF 5 forearm blood flow; FVC 5 forearm vascular conductance; % change 5 percent change in FBF or FVC from
baseline after L-NMMA.
*p , 0.01 vs. corresponding value in control. **p , 0.001 vs. corresponding value in control. †p , 0.01 vs. corresponding baseline value. ‡p , 0.001 vs. corresponding baseline
value.
Figure 2. Relationship between percent changes in forearm blood flow
(FBF) (left panel) and forearm vascular conductance (FVC) (right panel)
from baseline after administration of L-NMMA and basal plasma levels of
BNP in control subjects (open circles) and patients with congestive heart
failure (closed circles).
Figure 3. Relationship between percent changes in forearm blood flow
(FBF) (left panel) and forearm vascular conductance (FVC) (right panel)
from baseline after administration of L-NMMA and basal plasma levels of
NOx in control subjects (open circles) and patients with congestive heart
failure (closed circles).
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values for percent change in FBF at the highest dose of
L-NMMA were 33% in 18 normal subjects and 35% in 10
patients with NYHA functional class II to IV heart failure
using plethysmography. Their results are in agreement with
our results.
Recently, Carville et al. (11) demonstrated that vasocon-
strictive response to L-NMMA varied according to the
NYHA classification of heart failure. Thus, the percent
change in FBF after L-NMMA administration in patients
with moderate heart failure (NYHA functional class I or II)
was similar (57%) to that in control subjects (55%), and that
in patients with severe heart failure (NYHA functional class
III or IV) was reduced (43%). Those results, however, are
not entirely consistent with those of previous studies and the
present study. The difference in results suggests that NYHA
classification of heart failure may be inadequate because it is
subjective. The use of plasma BNP levels in the present
study provides a more objective measure for the classifica-
tion of the severity of heart failure.
These previous studies and the present study show that
vasoconstrictive response to L-NMMA in patients with
CHF is preserved or exaggerated, suggesting that basal NO
production and release in patients with CHF may be normal
or increased. However, Katz et al. (6) demonstrated that
administration of L-NMMA significantly lowered FBF by
25% in normal subjects but did not have this effect in
patients with CHF. Those results accord with the majority
of previous experimental studies (19,20). We cannot explain
the differences between the findings of the Katz et al. study
and the present data by differences in the severity of heart
failure, because basal FBF in the patients in the Katz et al.
study was low (2.3 6 0.3 ml/min/dl), suggesting moderate
or severe heart failure. One possible reason might be that
a smaller dose of L-NMMA (20 mmol) was used than in
the present study (100 mmol) and previous studies (60 to
145 mmol) (7–9,11). Kubo et al. (7) showed that de-
creases in FBF during infusion of low doses of L-NMMA
were significant but smaller than during infusion of high
doses of L-NMMA, and those findings might support
this explanation.
Enhanced production of NO in patients with severe
heart failure. Nitric oxide is synthesized from L-arginine
by calcium-dependent and -independent NO synthases, a
family of isoenzymes with distinct functional, biochemical,
and regulatory properties (21,22). The calcium-dependent
NO synthase in the endothelial cells plays an important role
in the regulation of peripheral circulation. However, recent
studies have shown the development of endothelial dysfunc-
tion in the peripheral resistance vessels of patients with
CHF (3–5,8) and a decrease in endothelial-NO synthase
expression in a dog model of heart failure (23), suggesting
that endothelial NO production is impaired in CHF. In this
respect, it seems probable that the increased basal release of
NO originates from another isoform of NO synthase, an
inducible calcium-independent NO synthase (24), which
can produce large amounts of NO. Indeed, in the present
study, the plasma NOx level in the patient with the highest
level of NOx (64 mmol/liter) was approximately 20 times
higher than that in normal subjects. This difference may not
be entirely accounted for by increased endothelial NO
production.
In preliminary studies, we measured FBF and venous
NOx levels before and during intra-arterial infusion of
30 mg/min of acetylcholine in four normal subjects (data not
shown). Although we observed a greater than 10-fold
increase in blood flow over the baseline in response to
acetylcholine, the increase in NOx was limited to approxi-
mately 80%. This finding suggests that the large amount of
NO in patients with severe heart failure might be produced
not by endothelial NO synthase but by inducible NO
synthase. However, our results do not allow us to draw any
conclusions as to whether the increased NO in CHF
patients is produced in the forearm tissue and/or in the
myocardium.
A recent study demonstrated that gene expression of
inducible NO synthase was increased in the skeletal muscle
of patients with severe heart failure (25), suggesting the
possibility of enhanced local production of NO in the
forearm tissue. In the present study, the enhanced vasocon-
strictive response to L-NMMA proportional to the severity
of heart failure is consistent with the hypothesis of an
association between severe heart failure and the expression
of inducible NO synthase in the peripheral vascular wall (8).
In the present study, by contrast, we found a nonsignif-
icant trend toward a lesser effect of L-NMMA on FBF and
FVC in patients with mild heart failure (BNP ,100 pg/ml)
compared with control subjects. It is difficult to assess the
meaning of this finding from our data. However, it might
possibly be suggested that in patients with mild heart
failure, NO produced by inducible NO synthase is not
present, whereas endothelium-derived NO production is
still impaired, resulting in a decrease in NO production.
We believe that basal production and release of NO is
enhanced in severe heart failure. It should be noted, how-
ever, that heightened vasoconstrictor tone is present in heart
failure, which, in this setting, may accentuate the effects of
any additional vasoconstricting agent. Because we did not
measure the diameter of brachial artery, the possibility of a
direct constricting effect of L-NMMA on the conduit vessel
cannot be excluded. Previous investigators reported that
L-NMMA had no direct constrictive effect on vascular
smooth muscle (26,27). However, further studies of basal
NO production in heart failure are needed, including
comparisons of the constrictive effects of a control agent and
of L-NMMA, to strengthen these conclusions.
Clinical implications. The increased basal production and
release of NO demonstrated in the present study may play
an important role in reducing the vascular resistance of the
peripheral vessels and maintaining adequate tissue perfu-
sion. However, these large amounts of NO may have
adverse consequences. The force of contraction in the
skeletal muscles is modulated by NO through impaired
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Ca21 activation of actin filaments, resulting in decreased
myofibrillar calcium sensitivity. Therefore, in patients with
severe heart failure, the increased availability of NO within
the skeletal muscle may affect the contractile force, resulting
in decreased capacity for exercise. Recent studies in humans
have shown that impaired endothelial function in the
peripheral vessels may be corrected by a variety of interven-
tions (28–33), though the clinical benefits of such improve-
ments in endothelial function have not been conclusively
demonstrated in patients. Therapeutic trials focused on the
increased production of NO in patients with severe heart
failure should also be planned.
Study limitations. In the present study, we measured
plasma NOx levels to assess basal NO production. However,
plasma NOx concentration is determined primarily from
exogenous sources such as diet (34), therapeutic medical
regimens (10) and renal excretion (35). Although all vaso-
dilating drugs were discontinued two or three days before
the date of the study, we cannot exclude the possibility that
exogenous nitrate and/or nitrite are included in the mea-
surements. Another limitation is the question of whether
the percent changes in FBF and FVC after L-NMMA
precisely reflect basal NO production and release. However,
the percent changes in FBF and FVC after L-NMMA
correlated weakly but significantly with plasma NOx levels,
while the absolute changes in FBF did not. These findings
suggest that the percent changes in FBF and FVC after
L-NMMA partly reflect basal NO production. Still, NOx
measurements before and after administration of
L-NMMA, which were performed in a previous study (7),
will be needed to clarify local NO production in patients
with heart failure.
Conclusions. The present study demonstrated that vaso-
constrictive response to L-NMMA in patients with CHF
was preserved or enhanced in proportion to the plasma BNP
level, indicating a close relationship between the contribu-
tion of NO to basal vasomotor tone and the severity of heart
failure. However, the mechanism behind these observations
remains to be clarified, and further studies are needed to
confirm these findings.
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